2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 576

Possibility of Extension of the Administration Interval of Tocilizumab in the Treatment of Rheumatoid Arthritis
Abstract Number: 577

Use of Subcutaneous MTX Does Not Prolong the Use of Traditional DMARD in Multi-DMARD Regimens and Has Insignificant Differences in Liver Enzymes Abnormalities When Compared with Oral MTX in Patients with Rheumatoid Arthritis: A Veteran Affairs Administrative Database Study
Abstract Number: 578

Study of the Production of Antinuclear Antibodies and Anti-Ds DNA Antibodies in Rheumatoid Arthritis Patients Treated with TNF Inhibitors
Abstract Number: 579

Methotrexate Does Not Influence 1-Year Bone Mineral Density in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 580

Treatment with Biologic Agents in Rheumatoid Arthritis and Mortality Risk in Clinical Practice
Abstract Number: 581

Optimization of Treatment Intervals of Tocilizumab and Golimumab By Measuring Serum Trough Levels in Rheumatoid Arthritis Patients
Abstract Number: 582

Biological Drugs Dose Tapering in Inflammatory Rheumatic Diseases: 2 Year Results at Basurto University Hospital
Abstract Number: 583

A Serological Biomarker of Active MMP3, but Total MMP3, Can Early Assess Treatment Efficacy and Differentiate Doses of Tocilizumab and an Early Change in Active MMP3, but Not Total MMP3, Is Associated with Radiographic Change at 1 Year
Abstract Number: 584

Positivity for Rheumatoid Factor Is Associated with a Better Short-Term Response and Long-Term Drug Retention of Abatacept: Results from Consecutive 508 Patients with Rheumatoid Arthritis in a Japanese Multicenter Registry
Abstract Number: 585

Outcomes after Discontinuing Tumor Necrosis Factor Inhibitor in Rheumatoid Arthritis: 2 Years of ‘post-Golimumab’ after Completion of the 5-Year Extension Study in Korea
Abstract Number: 586

Titer of Anti-Citrullinated Peptide Antibody Affects the Efficacy of First Biological Treatment in Rheumatoid Arthritis
Abstract Number: 587

Defining the Conditions Under Which Long-Term Glucocorticoid Treatment Has a Good Benefit-Risk Ratio
Abstract Number: 588

Prospective Study about Extension of Dosing Interval with Tocilizumab Therapy in Rheumatoid Arthritis Patients in Remission Maintenance
Abstract Number: 589

Adalimumab Concentration at 16 Weeks of Treatment Is Associated with Treatment Discontinuation within One Year
Abstract Number: 590

Expression Levels of Selected Genes May Predict Response to TNF Alpha Blockers or Rituximab in the Individual Rheumatoid Arthritis Patient

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].